Viemed Healthcare Announces Voting Results From Its Annual & Special Meeting of Shareholders

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (TSX:VMD.TO and NASDAQ:VMD), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, today announced the voting results from its annual and special meeting of shareholders held on June 10, 2021 (the " Meeting ") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 25,380,544, representing 64.13% of the total issued and outstanding shares in the capital of the Company.

Election of Directors

The eight candidates nominated for election to the Company's Board of Directors (the " Board ") and listed in the Company's management information and proxy circular dated April 30, 2021 (the " Circular "), were elected by at least a majority of the shareholders present in person or represented by proxy at the Meeting. The voting results are as follows:

Name	Votes For	% For	Votes Withheld	% Withheld
Casey Hoyt	22,752,331	96.14%	914,671	3.86%
W. Todd Zehnder	22,376,289	94.55%	1,290,713	5.45%
William Frazier	22,160,129	93.63%	1,506,873	6.37%
Randy Dobbs	22,437,938	94.81%	1,229,064	5.19%
Nitin Kaushal	19,025,825	80.39%	4,641,176	19.61%
Timothy Smokoff	22,440,514	94.82%	1,226,488	5.18%
Bruce Greenstein	22,074,330	93.27%	1,592,671	6.73%
Sabrina Heltz	23,011,497	97.23%	655,505	2.77%

Appointment of Auditors

The Company's shareholders have approved the appointment of Ernst & Young LLP as the auditor of the Company for the fiscal year ended December 31, 2021 and authorized the Board to fix the auditor's remuneration.

Amendments to the Articles of the Company

The shareholders passed an ordinary resolution approving certain amendments to the Articles of the Company with respect to the quorum requirement for meetings of shareholders, as more particularly described in the Circular.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.‎

For further information, please contact:‎

Glen Akselrod
Bristol Capital
‎905-326-1888‎
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.‎
‎337-504-3802‎
investorinfo@viemed.com

News Provided by GlobeNewswire via QuoteMedia

vmd viemed healthcare medical device investing vmd:ca Medical Device Investing

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials". A replay of the call will be available under "News, Events & Presentations" through Friday, February 14, 2025.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .